MCI 225

Drug Profile

MCI 225

Alternative Names: AA 10021; AA 10025; AA 10026

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Arachnova
  • Class Analgesics; Antidepressants; Irritable bowel syndrome therapies; Nootropics; Pyrimidines; Small molecules; Urologics
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin 3 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Pain; Stress incontinence

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
  • 24 Jul 2006 This compound is in active development for Pain, Stress incontinence and Irritable bowel Syndrome
  • 22 Jan 2003 Preclinical trials in Pain in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top